Daniel E. Meyers

TL;DR: The basics of the PD-1/PD-L1 axis and its clinical significance in non-small-cell lung cancer are covered, biomarkers that are predictive of treatment response, relevant clinical trials of PD-2/2/L1 blockade completed to date, and proposed mechanisms of acquired therapeutic resistance are proposed.

TL;DR: Data are the first to suggest that in a real-world setting, the prognostic value of LIPI may be tumor agnostic, as well as to investigate its applicability beyond NSCLC.

TL;DR: The combination of PD-1 blockade and RV appears to be an efficacious immunotherapeutic strategy for the treatment of BrCa, and warrants further investigation in early-phase clinical trials.

TL;DR: A case of aplastic anemia in a patient with metastatic melanoma secondary to dual ICB therapy, and the resolution of this patient’s AA with corticosteroids highlights the value of early detection and appropriate treatment of these rare immune-mediated adverse events.

TL;DR: Synergistic strategies to enhance the efficacy of OV include augmenting the host antitumor response through the insertion of therapeutic transgenes such as GM-CSF, utilization of the prime-boost strategy, and combining OV with immune-modulatory drugs such as cyclophosphamide, sunitinib, and immune checkpoint inhibitors.